Back to Journals » Journal of Asthma and Allergy » Volume 14

Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series

Authors Nucera E, Urbani S, Buonomo A, De Pasquale T, Rizzi A, Aruanno A, Pucci S

Received 4 December 2020

Accepted for publication 26 January 2021

Published 15 March 2021 Volume 2021:14 Pages 241—244

DOI https://doi.org/10.2147/JAA.S295748

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Luis Garcia-Marcos


Eleonora Nucera,1 Sara Urbani,1 Alessandro Buonomo,1 Tiziana De Pasquale,2 Angela Rizzi,1 Arianna Aruanno,1 Stefano Pucci2

1Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2Civitanova Marche Hospital, Civitanova Marche, Italy

Correspondence: Eleonora Nucera
Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo F. Vito, 1, Rome, 00168, Italy
Tel +39 3394475931
Fax +06 30156999
Email [email protected]

Abstract: Gadolinium-based contrast agents (GBCAs) are considered to be safe, although sometimes patients report a hypersensitivity reaction when undergoing magnetic resonance imaging (MRI). The mechanisms of these reactions and of the sensitization to GBCAs are still largely unknown. We describe four cases of patients who experienced immediate adverse reactions to GBCAs with a demonstrated cutaneous hypersensitivity suggesting an IgE-mediated mechanism.

Keywords: gadolinium-based contrast agents, hypersensitivity, IgE-mediated reactions

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]